Host State partner
Department of Energy and Economic Diversification
Conference Dinner Partner
Cook Medical
At Cook Medical, we are passionate about making unique, quality medical devices and connecting with people to improve lives. Founded on inventing, manufacturing and delivering medical devices, we provide healthcare professionals with the tools they need to help their patients return to living.
In Australia, Cook employs more than 800 people and is one of Queensland’s largest medical device manufacturers and exporters. We export 94% of our locally manufactured products to medical providers around the world with devices across two product families: endovascular grafts for the treatment of vascular disease and in-vitro fertilisation to assist those trying to conceive a child. Both product lines were invented and developed in Australia. The former developed in partnership with Perth-based vascular clinicians, and the latter with pioneering IVF units in Melbourne and Sydney.
As part of a global network of companies, Cook offers a range of state-of-the-art treatment options for physicians and patients in Australian hospitals. This broad product offering supports both diagnostic and minimally invasive therapeutic procedures, serving nearly 60 clinical specialties, reaching almost every area of the hospital.
In Australia, Cook employs more than 800 people and is one of Queensland’s largest medical device manufacturers and exporters. We export 94% of our locally manufactured products to medical providers around the world with devices across two product families: endovascular grafts for the treatment of vascular disease and in-vitro fertilisation to assist those trying to conceive a child. Both product lines were invented and developed in Australia. The former developed in partnership with Perth-based vascular clinicians, and the latter with pioneering IVF units in Melbourne and Sydney.
As part of a global network of companies, Cook offers a range of state-of-the-art treatment options for physicians and patients in Australian hospitals. This broad product offering supports both diagnostic and minimally invasive therapeutic procedures, serving nearly 60 clinical specialties, reaching almost every area of the hospital.
Welcome Reception Partner
FB Rice
Founded over 75 years ago, FB Rice is Australia’s leading independent intellectual property firm. Responsive, thoughtful, and reliable, we partner with clients to protect medical technology and digital health innovations through expert IP guidance to safeguards ideas and maximise their commercial value.
Drawing on their deep academic, industry and practical experience, our dedicated Medical Technology Group provides the highest quality advice on intellectual property matters relating to medical technology, including patentability and infringement, drafting and prosecution of patent applications and portfolio management. We also provide comprehensive due diligence advice including conducting and reporting on patent searches, with extensive experience across a range of areas including bionics, orthopaedics, optics and cardiovascular devices.
Our firm additionally has experience in the areas of nanotechnology, biotechnology, and engineering, and we collaborate with our medical technology clients to provide a full range of IP services across their technology's life cycle.
A proud supporter of innovation, FB Rice works with a broad range of domestic and international clients ranging in size from start-up through to large multinationals including manufacturers, software companies, universities, hospitals, co-operative research centres and research institutes. Just as Australia’s researchers and engineers continue pushing the boundaries of innovation and knowledge, we are deeply committed to constantly improving our own capabilities and work closely with local industry bodies and networks to ensure that we deliver a superior service every time.
As an independent firm, FB Rice has a distinct advantage - our sole focus is the success of our clients. This long-standing commitment to client experience is reflected in our accolades, including the Client Choice Awards in which FB Rice has been recognised as Australia’s Best Specialist IP Firm for nine consecutive years. Our knowledge, experience and client focus means you will always be supported by experts who know what you’re talking about and are passionate about helping you achieve success.
At FB Rice, we champion innovation and create value.
Drawing on their deep academic, industry and practical experience, our dedicated Medical Technology Group provides the highest quality advice on intellectual property matters relating to medical technology, including patentability and infringement, drafting and prosecution of patent applications and portfolio management. We also provide comprehensive due diligence advice including conducting and reporting on patent searches, with extensive experience across a range of areas including bionics, orthopaedics, optics and cardiovascular devices.
Our firm additionally has experience in the areas of nanotechnology, biotechnology, and engineering, and we collaborate with our medical technology clients to provide a full range of IP services across their technology's life cycle.
A proud supporter of innovation, FB Rice works with a broad range of domestic and international clients ranging in size from start-up through to large multinationals including manufacturers, software companies, universities, hospitals, co-operative research centres and research institutes. Just as Australia’s researchers and engineers continue pushing the boundaries of innovation and knowledge, we are deeply committed to constantly improving our own capabilities and work closely with local industry bodies and networks to ensure that we deliver a superior service every time.
As an independent firm, FB Rice has a distinct advantage - our sole focus is the success of our clients. This long-standing commitment to client experience is reflected in our accolades, including the Client Choice Awards in which FB Rice has been recognised as Australia’s Best Specialist IP Firm for nine consecutive years. Our knowledge, experience and client focus means you will always be supported by experts who know what you’re talking about and are passionate about helping you achieve success.
At FB Rice, we champion innovation and create value.
Early Stage Innovation Forum Partner
West Pharmaceutical Services
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in 2025 generated $3.1 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
Website links
Corporate site: https://www.westpharma.com/
Blog: https://www.westpharma.com/blog
Social Media links
LinkedIn: https://www.linkedin.com/company/west-pharmaceutical-services/posts/?feedView=all
YouTube: youtube.com/user/WestFYI
Website links
Corporate site: https://www.westpharma.com/
Blog: https://www.westpharma.com/blog
Social Media links
LinkedIn: https://www.linkedin.com/company/west-pharmaceutical-services/posts/?feedView=all
YouTube: youtube.com/user/WestFYI
Session Partner
FB Rice
Founded over 75 years ago, FB Rice is Australia’s leading independent intellectual property firm. Responsive, thoughtful, and reliable, we partner with clients to protect medical technology and digital health innovations through expert IP guidance to safeguards ideas and maximise their commercial value.
Drawing on their deep academic, industry and practical experience, our dedicated Medical Technology Group provides the highest quality advice on intellectual property matters relating to medical technology, including patentability and infringement, drafting and prosecution of patent applications and portfolio management. We also provide comprehensive due diligence advice including conducting and reporting on patent searches, with extensive experience across a range of areas including bionics, orthopaedics, optics and cardiovascular devices.
Our firm additionally has experience in the areas of nanotechnology, biotechnology, and engineering, and we collaborate with our medical technology clients to provide a full range of IP services across their technology's life cycle.
A proud supporter of innovation, FB Rice works with a broad range of domestic and international clients ranging in size from start-up through to large multinationals including manufacturers, software companies, universities, hospitals, co-operative research centres and research institutes. Just as Australia’s researchers and engineers continue pushing the boundaries of innovation and knowledge, we are deeply committed to constantly improving our own capabilities and work closely with local industry bodies and networks to ensure that we deliver a superior service every time.
As an independent firm, FB Rice has a distinct advantage - our sole focus is the success of our clients. This long-standing commitment to client experience is reflected in our accolades, including the Client Choice Awards in which FB Rice has been recognised as Australia’s Best Specialist IP Firm for nine consecutive years. Our knowledge, experience and client focus means you will always be supported by experts who know what you’re talking about and are passionate about helping you achieve success.
At FB Rice, we champion innovation and create value.
Drawing on their deep academic, industry and practical experience, our dedicated Medical Technology Group provides the highest quality advice on intellectual property matters relating to medical technology, including patentability and infringement, drafting and prosecution of patent applications and portfolio management. We also provide comprehensive due diligence advice including conducting and reporting on patent searches, with extensive experience across a range of areas including bionics, orthopaedics, optics and cardiovascular devices.
Our firm additionally has experience in the areas of nanotechnology, biotechnology, and engineering, and we collaborate with our medical technology clients to provide a full range of IP services across their technology's life cycle.
A proud supporter of innovation, FB Rice works with a broad range of domestic and international clients ranging in size from start-up through to large multinationals including manufacturers, software companies, universities, hospitals, co-operative research centres and research institutes. Just as Australia’s researchers and engineers continue pushing the boundaries of innovation and knowledge, we are deeply committed to constantly improving our own capabilities and work closely with local industry bodies and networks to ensure that we deliver a superior service every time.
As an independent firm, FB Rice has a distinct advantage - our sole focus is the success of our clients. This long-standing commitment to client experience is reflected in our accolades, including the Client Choice Awards in which FB Rice has been recognised as Australia’s Best Specialist IP Firm for nine consecutive years. Our knowledge, experience and client focus means you will always be supported by experts who know what you’re talking about and are passionate about helping you achieve success.
At FB Rice, we champion innovation and create value.
Quantum Australia
Established in 2024, Quantum Australia helps drive the growth of Australia’s quantum ecosystem by delivering programs that support the National Quantum Strategy.
Primarily funded by the Australian Government, with additional support from state governments, industry and universities, we work closely with universities as key delivery partners. We also engage end-user industry and the broader quantum industry to help identify and develop priority use cases and support industry adoption.
As a national convener, we connect and coordinate activity across Australia’s quantum ecosystem, helping align effort and present a coherent Australian presence on the global stage.
Through raising awareness of quantum capability, supporting commercialisation pathways, encouraging responsible innovation and building quantum readiness across industry, we create opportunities that drive economic value, benefit communities, and help position Australia as a global leader in quantum.
Primarily funded by the Australian Government, with additional support from state governments, industry and universities, we work closely with universities as key delivery partners. We also engage end-user industry and the broader quantum industry to help identify and develop priority use cases and support industry adoption.
As a national convener, we connect and coordinate activity across Australia’s quantum ecosystem, helping align effort and present a coherent Australian presence on the global stage.
Through raising awareness of quantum capability, supporting commercialisation pathways, encouraging responsible innovation and building quantum readiness across industry, we create opportunities that drive economic value, benefit communities, and help position Australia as a global leader in quantum.
RMIT University
RMIT University is a global university of technology, design and enterprise, recognised for industry engagement, applied research and innovation translation.
RMIT’s Discovery to Device (D2D) Prototyping Facility supports the rapid development and translation of next-generation medtech, healthtech and advanced manufacturing technologies.
D2D brings together capabilities across flexible and printed electronics, sensors, microfabrication, biomedical prototyping, advanced materials and design-for-manufacture to help accelerate the pathway from concept through to functional prototype and early-stage validation.
Designed as an industry-connected translation environment, D2D works with researchers, startups, clinicians and companies to help de-risk technologies, explore manufacturability, and bridge the gap between research outcomes and real-world deployment.
RMIT’s Discovery to Device (D2D) Prototyping Facility supports the rapid development and translation of next-generation medtech, healthtech and advanced manufacturing technologies.
D2D brings together capabilities across flexible and printed electronics, sensors, microfabrication, biomedical prototyping, advanced materials and design-for-manufacture to help accelerate the pathway from concept through to functional prototype and early-stage validation.
Designed as an industry-connected translation environment, D2D works with researchers, startups, clinicians and companies to help de-risk technologies, explore manufacturability, and bridge the gap between research outcomes and real-world deployment.
SeerPharma Pty Ltd
SeerPharma is a private consulting organisation supporting medical device and pharmaceutical companies across the Asia-Pacific (APAC) region with expertise in Quality Systems, regulatory compliance, and Good Manufacturing Practice (GMP). With more than 35 years of experience, the company works with organisations involved in the development, manufacture, and lifecycle management of regulated healthcare products, with a strong focus on helping medical device companies maintain compliance and operational excellence.
Operating with team members in Melbourne, Sydney, Singapore, and India, plus supported by an affiliate in the United Kingdom, SeerPharma assists organisations in establishing and maintaining effective quality and regulatory frameworks. The team helps ensure that facilities, equipment, processes, and computerised systems meet the expectations of global regulatory authorities and standards bodies, including the FDA, TGA, EMA, WHO, PIC/S, ISO, and ICH. For medical device organisations, this includes supporting alignment with ISO 13485 and other regulatory requirements governing device design, manufacturing, and post-market oversight.
SeerPharma regularly supports medical device companies in preparing for and responding to regulatory inspections and audits from authorities such as the Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and European regulators. The team also performs independent supplier and GMP audits across the Asia-Pacific region on behalf of industry clients and in preparation for Notified Bodies. These activities help organisations strengthen supply chain oversight and ensure ongoing compliance in a highly regulated environment.
Training and capability development are key components of SeerPharma’s services. The firm provides practical training in quality and GMP compliance across the product lifecycle, from research and development through manufacturing, distribution, and post-market surveillance. This commitment to professional development has led SeerPharma to develop and deliver an internationally recognised Postgraduate GMP Program at the University of Technology Sydney (UTS), supporting professionals working in pharmaceutical and medical device sectors throughout the APAC region.
SeerPharma also helps organisations modernise their quality systems through digital transformation initiatives. Its Software Solutions team implements electronic Quality Management Systems (eQMS) and paperless manufacturing solutions using the MasterControl platform. These solutions help medical device manufacturers streamline processes, improve documentation control, and strengthen their ability to demonstrate regulatory compliance.
In addition to consulting and technology services, SeerPharma provides experienced Quality Assurance and compliance professionals on a contract basis. These specialists support projects such as quality system implementation, remediation activities, inspection readiness, and process improvement initiatives where short-term expertise is required.
Through its consulting, training, technology, and resourcing services, SeerPharma aims to
“Advance Quality and GMP best practices in the APAC region”, supporting medical device organisations in delivering safe, effective, and compliant products to global markets.
www.seerpharma.com
Operating with team members in Melbourne, Sydney, Singapore, and India, plus supported by an affiliate in the United Kingdom, SeerPharma assists organisations in establishing and maintaining effective quality and regulatory frameworks. The team helps ensure that facilities, equipment, processes, and computerised systems meet the expectations of global regulatory authorities and standards bodies, including the FDA, TGA, EMA, WHO, PIC/S, ISO, and ICH. For medical device organisations, this includes supporting alignment with ISO 13485 and other regulatory requirements governing device design, manufacturing, and post-market oversight.
SeerPharma regularly supports medical device companies in preparing for and responding to regulatory inspections and audits from authorities such as the Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and European regulators. The team also performs independent supplier and GMP audits across the Asia-Pacific region on behalf of industry clients and in preparation for Notified Bodies. These activities help organisations strengthen supply chain oversight and ensure ongoing compliance in a highly regulated environment.
Training and capability development are key components of SeerPharma’s services. The firm provides practical training in quality and GMP compliance across the product lifecycle, from research and development through manufacturing, distribution, and post-market surveillance. This commitment to professional development has led SeerPharma to develop and deliver an internationally recognised Postgraduate GMP Program at the University of Technology Sydney (UTS), supporting professionals working in pharmaceutical and medical device sectors throughout the APAC region.
SeerPharma also helps organisations modernise their quality systems through digital transformation initiatives. Its Software Solutions team implements electronic Quality Management Systems (eQMS) and paperless manufacturing solutions using the MasterControl platform. These solutions help medical device manufacturers streamline processes, improve documentation control, and strengthen their ability to demonstrate regulatory compliance.
In addition to consulting and technology services, SeerPharma provides experienced Quality Assurance and compliance professionals on a contract basis. These specialists support projects such as quality system implementation, remediation activities, inspection readiness, and process improvement initiatives where short-term expertise is required.
Through its consulting, training, technology, and resourcing services, SeerPharma aims to
“Advance Quality and GMP best practices in the APAC region”, supporting medical device organisations in delivering safe, effective, and compliant products to global markets.
www.seerpharma.com
BioInnovation Spotlight Session
Porex Technologies Sdn Bhd
Syngenis
Syngenis Labs Ltd is an Australian-based contract research organisation advancing the future of precision medicine through the manufacture of antisense oligonucleotides. Working with research institutions, biotechnology firms, and pharmaceutical companies, we provide high-quality solutions that enable the development of next-generation diagnostics and therapeutics from bench to clinic.
